L. Duck Archives - Page 2 of 2

Metastatic breast phyllodes tumour: is chemotherapy effective?

BJMO - volume 11, issue 1, february 2017

C. Quaghebeur MD, N. Whenham MD, J.P. Machiels MD, PhD, J-P. Haxhe MD, A-P. Schillings MD, E. Laterre MD, X. Catteau MD, R. Poncin MD, L. Duck MD

SUMMARY

Breast phyllodes tumours account for less than 0.5% of breast tumours, their diagnosis is therefore often made after pathological exam. They are fibroepithelial lesions of the breast, and are classified as benign, borderline or malignant. For malignant phyllodes tumours, aggressive behaviour with risk of local and distant recurrence may be seen. Therefore, at least one centimetre free-margins, or mastectomy, should be preferred for local malignant tumours. No prospective randomised data exist to elucidate the role of adjuvant chemotherapy, but radiotherapy should probably be offered after breast conservative surgery for borderline and malignant tumours. For metastatic disease, there is no standard chemotherapy regimen. Doxorubicin is the main recommended drug, based on scarce data. Palliative surgery or radiotherapy may also be offered. We present here a patient with lung metastatic disease who partially responded to a platin-etoposide regimen after doxorubicin failure, and make a short review of the literature.

(BELG J MED ONCOL 2017;11(1):26–28)

Adjuvant treatment for uterine cancers, a review of the current evidence

BJMO - volume 10, issue 2, april 2016

L. Duck MD, J-F. Baurain MD, PhD, C. Kirkove MD, R. Poncin MD, A. Barbeaux MD, V. Malvaux MD, J-C. Verougstraete MD, J-L. Squifflet MD, PhD, M. Luyckx MD

Summary

To date, the main treatment of loco-regional uterine cancer is surgery. The benefit of adjuvant treatment depends on the subtype of cancer, stage, and risk factors. We describe here the current evidence-based data supporting the administration of adjuvant treatment after surgery, with a focus on chemotherapy.

(BELG J MED ONCOL 2016;10(2):63–68)

Thrombo-embolic events in cancer patients with impaired renal function

BJMO - volume 9, issue 2, may 2015

I. Elalamy MD, PhD, J-L. Canon MD, A. Bols MD, PhD, W. Lybaert MD, L. Duck MD, K. Jochmans MD, L. Bosquée MD, PhD, M. Peeters MD, PhD, A. Awada MD, PhD, P. Clement MD, PhD, S. Holbrechts MD, PhD, J-F. Baurain MD, PhD, J. Mebis MD, J. Nortier MD, PhD

Venous thromboembolism is a frequent cause of mortality and morbidity in patients with malignancy. Thrombosis is one of the leading causes of death in patients with malignancy after cancer itself. As such, prompt recognition and treatment of venous thromboembolism are required in order to reduce the risk of venous thromboembolism-related mortality. This report reviews the interrelationship between cancer, renal insufficiency and venous thromboembolism. The working group behind this review article concludes that low molecular weight heparins decrease the risk of recurrent venous thrombosis in cancer patients without increasing major bleeding complications. Low molecular weight heparins are therefore recommended as first line antithrombotic treatment in cancer patients with a clear clinical benefit. In patients with renal dysfunction, who are at increased risk of bleeding and of thrombotic complications, preference should be given to unfractionated heparin or a low molecular weight heparin with a mean molecular weight such as tinzaparin, having less risk of plasma accumulation and offering the possibility to maintain full therapeutic dose.

(BELG J MED ONCOL 2015;9(2):53–60)